TMS
Fuchu
About TMS
TMS is a Tokyo-based clinical-stage biotech company that unlocks fungus-derived SMTP small molecule compound group. SMTPs have novel dual mode of action, both thrombolytic and anti-inflammatory. The lead compound TMS-007 is in Phase IIa clinical trial indicated for acute ischemic stroke and partnered with Biogen.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $8.1M
- Last round: Series Unknown (Jun 2017)
- Website: tms-japan.co.jpenindex.html
- Phone: +81-42-306-5087
Industries & Categories
Biotechnology, Life Science, Medical, Nursing and Residential Care, Pharmaceutical
Canonical: https://fsome.com/organization/tms-24914 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.